About Veralox Therapeutics
Veralox Therapeutics is a private company based in Frederick, Maryland, incorporated in 2018 in Delaware. It has reported $39,911,021 raised in three offerings on Form D since May 2019. Its chief executive is Jonathan Mow.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jun 1, 2023 | Jun 21, 2023 | $24,013,521of $24.9M target | 14 | $1.7M | Equity, Offer and sale of shares of preferred stock and the underlying shares of common stock issuable upon conversion thereof.Rule 506(b) | Form D ↗ |
| Jun 10, 2021 | Jul 7, 2021 | $14,437,500of $22.7M target | 17 | $849K | Equity, Offer and sale of shares of preferred stock and the underlying shares of common stock issuable upon conversion thereof.Rule 506(b) | Form D ↗ |
| May 10, 2019 | May 22, 2019 | $1,460,000of $4.0M target | 6 | $243K | DebtRule 506(b) | Form D ↗ |
| Total, three offerings | $39,911,021 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Veralox Therapeutics's Form D filed Jun 21, 2023.
Earlier filings also listed Jeffrey Strovel (chief executive officer and director, last listed Jul 2021), Christopher Gagliardi (director, last listed Jul 2021), Matthew Boxer (executive officer and director, last listed May 2019), Jonathan Behr (director, last listed May 2019) and David Maloney (executive officer and director, last listed May 2019).